Huikede Sheng

Huikede Sheng is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. The company's primary focus is on addressing relapsed or refractory hematologic malignancies through its proprietary cellular engineering platform. Its lead program, HKDS-001, is a CD19-targeted CAR-T cell therapy currently undergoing Phase 1/2 clinical evaluation in patients with B-cell malignancies. Huikede Sheng aims to improve the accessibility and efficacy of immunotherapy by optimizing manufacturing processes and cell design. The company operates within the robust biotech ecosystem of Beijing, focusing on translating advanced research into clinical applications for cancer patients.